The initiation of patient enrolment in the STARS DAPT trial marks an important milestone for Abluminus np. While contemporary ...

Concept Medical has enrolled the first patients in the STARS DAPT global trial evaluating its polymer-free Abl ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced continued progress in the clinical and commercial advancement of its Voro® ...

Even as they’re pushing the boundaries of research and discovery with AI, UC scientists are asking the right questions about ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...

Introduction The increasing incidence of type 2 diabetes mellitus (T2DM) among women of reproductive age poses significant health risks for both mothers and their fetuses. Optimising blood glucose ...

Researchers explored the effects of walking frequency and intensity on chemotherapy-related fatigue in patients with breast cancer.

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was selected by Boehringer Ingelheim, the leading biopharmaceutical company providing ...

BOSTON, Jan. 20, 2026) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...